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ABSTRACT
Introduction: Children experience considerable
morbidity and mortality due to tobacco smoke
exposure. Tobacco control policies may benefit child
health by reducing this exposure. We aim to
comprehensively assess the effects of the range of
tobacco control policies advocated by the WHO on
perinatal and child health.
Methods and analysis: We will systematically
search 19 electronic literature databases (from
inception) for published studies, and the WHO
International Clinical Trials Registry Platform for
unpublished studies. Additional work will be
identified via handsearching references and citations,
and through consulting an international panel of
experts. No language restrictions will apply. Following
Cochrane Effective Practice and Organisation of Care
(EPOC) guidelines, randomised and clinical controlled
trials, controlled before-and-after studies, and
interrupted time series designs, are eligible. Studies
of interest will assess the impact of any of the
WHO-advocated tobacco control policies contained in
the MPOWER acronym (except ‘Monitoring tobacco
use’) on at least one outcome of interest among
children aged 0–12 years. The primary outcomes are:
perinatal mortality, preterm birth, asthma
exacerbations requiring hospital attendance and
respiratory infections requiring hospital attendance.
Data will be extracted using customised forms and
authors will be contacted to obtain missing
information. Risk of bias will be assessed using
EPOC criteria. Findings will be reported in narrative
and tabular form. Between-study heterogeneity will
be assessed clinically and statistically using I2.
If appropriate and possible, random-effects
meta-analysis will be conducted for each unique
combination of intervention and outcome. Subgroup
analyses will be performed to assess the influence of
the comprehensiveness of each policy, and to
explore the impact of each policy according to
socioeconomic status.
Ethics and dissemination: No ethical assessment is
necessary as we will summarise existing studies. We
will publish our findings in a peer-reviewed scientific
journal.
Trial registration number: PROSPERO;
CRD42015023448.
INTRODUCTION
Tobacco use remains the primary cause
of preventable mortality worldwide.1
Unwillingly, over 40% of children suffer from
the health risks associated with regular
exposure to other people’s tobacco smoke
(secondhand smoke, SHS).2 Respiratory dis-
eases among children account for over half
of the annual 10.9 million healthy life years
lost globally as a result of SHS exposure.2 In
addition, tobacco smoke exposure before
birth and during early life is associated with
a range of adverse pregnancy outcomes
including stillbirth and low birth weight,3 as
well as with congenital anomalies and
sudden infant death syndrome (SIDS).4 5
Governmental action to protect infants and
children from the health dangers of SHS
during these critical phases of development
is of paramount importance, as children
have no means by which to regulate their
own level of exposure.
Following on from its 2003 Framework
Convention on Tobacco Control (FCTC), the
WHO has developed a package of six key
policy recommendations summarised in the
MPOWER acronym (ie, Monitor tobacco use
and prevention policies; Protect people from
tobacco smoke; Offer help to quit tobacco
use; Warn about the dangers of tobacco;
Enforce bans on tobacco advertising, promo-
tion and sponsorship; and Raise taxes on
tobacco).1 Despite progress having been
made regarding the implementation of
MPOWER policies in individual countries,
the majority of the world’s population
remains unprotected by even a single
tobacco control policy at the highest level.1
Given the substantial contribution of chil-
dren to the global burden of disease due to
SHS exposure, and their inability to inﬂu-
ence SHS exposure, it is surprising that
impact evaluations of tobacco control pol-
icies have generally excluded children,
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focusing on adult health and smoking rates.6–9 In the
ﬁrst systematic review on the health impact of smoke-free
policies (‘P’ in MPOWER) among children, we recently
showed important reductions in preterm birth and
severe asthma exacerbations,10 highlighting the consid-
erable potential for tobacco control to beneﬁt child
health. Additional studies are now also showing positive
impact on other outcomes, such as paediatric respiratory
infections and perinatal mortality, and of other tobacco
control policies, such as tobacco taxation, on early-life
health.11–16 A comprehensive assessment of the impact
of the different MPOWER policies on child health is,
however, lacking.
We therefore aim to systematically investigate the
impact of tobacco control policies on key perinatal and
child health outcomes. This will provide an update of
our recent systematic review and meta-analysis on smoke-
free legislation and early-life health,10 while at the same
time signiﬁcantly broadening the scope of this work by
evaluating the child health impact of a much wider
range of WHO-advocated tobacco control policies.
Where possible and appropriate, we will employ
meta-analysis to produce aggregate effect measures of
the association between the policies and each outcome.
By providing a comprehensive perspective on the health
impact of a range of tobacco control policies among
children, who unwillingly contribute importantly to the
overall burden of SHS-associated adverse health out-
comes, our ﬁndings can guide policy-making in those
parts of the world where MPOWER implementation is
lagging behind. We will develop policy recommenda-
tions and identify the key remaining knowledge gaps in
the ﬁeld, and, accordingly, propose future research
priorities.
METHODS
We followed the PRISMA-P guideline for preferred
reporting for systematic review and meta-analysis proto-
cols in preparing this protocol.17 This protocol is regis-
tered with the PROSPERO prospective register of
systematic reviews: CRD42015023448.
Eligibility criteria
We will select studies based on the criteria outlined
below.
Study designs
The methodological approach advocated by the
Cochrane Effective Practice and Organisation of Care
(EPOC) group will direct selection of the most robust
study designs for the primary analyses.18 This is import-
ant as it is likely that the majority of available evidence
will need to be derived from quasi-experimental and
other types of observational studies, which are inherently
at risk of bias.10 19 Following EPOC recommendations,
we will therefore restrict our main analyses to the
following study designs: randomised controlled trials
(RCTs; including cluster RCTs), controlled clinical
trials (CCTs; including cluster CCTs), interrupted time
series (ITS studies; including difference-in-difference
(DID) designs20), and controlled before-and-after
(CBA) studies. Based on previous experience,10 the
number of studies in this area that ﬁt the EPOC design
criteria is expected to be small. We will therefore, for
the primary outcomes, also identify any uncontrolled
before-and-after (UBA), prospective or retrospective
cohort, case–control and nested case–control studies.
For the primary outcomes (see below) we will via sensi-
tivity analyses explore whether the additional inclusion
of these study types has any impact on the effect
estimates.
Participants
We will include studies in which the study participants
are fetuses (for the outcome ‘stillbirth’) or children. As
our primary interest is in evaluating the impact of
tobacco control policies on child health via reducing
SHS exposure rather than via reducing active smoking
among children, and to also minimise any confounding
by active smoking among children, this review will focus
on children aged under 12 years. We will, however,
include studies that included children up to age 20 years
as long as the majority (ie, >50%) of the study popula-
tion is aged <12 years during the at-risk period. Studies
that included both adults and children will be eligible
for inclusion if paediatric subgroup data are available
that fulﬁl these criteria.
Interventions
Of interest are population-level and individual-level gov-
ernmental policies that comply with any of the
WHO-advocated tobacco control policies covered in the
MPOWER acronym, with the exception of ‘M’ for
‘Monitor tobacco use and prevention policies’. This is
because monitoring, per se, is not expected to improve
early-life health outcomes. As categorised according to
the (M)POWER acronym, the following policies, insti-
tuted at any governmental level (eg, city, state, country),
will thus be eligible:
▸ P (Protect people from tobacco smoke)
– Legislation to create smoke-free public environ-
ments (both indoor and outdoor smoke-free pol-
icies are of interest)
▸ O (Offer help to quit tobacco use)
– Tobacco cessation advice or interventions offered
through healthcare services
– Free telephone quit lines
– Providing access to free or low-cost cessation
medicines
▸ W (Warn about the dangers of tobacco)
– Health warnings on tobacco products
– Plain packaging of tobacco products
– Mass media campaigns to educate public about
dangers of tobacco
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▸ E (Enforce bans on tobacco advertising, promotion
and sponsorship)
– See appendix to Guidelines for implementation of
Article 13 of the WHO FCTC for a non-exhaustive
list of forms of advertising, promotion and sponsor-
ship within the terms of the FCTC21
▸ R (Raise taxes on tobacco)
– Tax increase on tobacco products
Comparators
Depending on the study design, eligible comparators
include:
▸ A population living in a geographical area where no
change in the policy of interest occurred at the time
when the policy was implemented in the geograph-
ical area of interest (ie, in the control area the policy
has either already been implemented or has not yet
been implemented). Examples include (cluster)
RCTs and DID studies.
▸ The population living in the geographical study area
of interest before the implementation of the policy of
interest in that particular area. This applies to ITS
studies, for example.
Outcomes
We are interested in studies reporting perinatal, infant
and paediatric health outcomes that are known to be
inﬂuenced by antenatal or postnatal tobacco smoke
exposure. These are: perinatal, infant and child mortal-
ity (including stillbirth), preterm birth, low birth weight,
being small for gestational age, congenital anomalies
and childhood respiratory disorders (including wheez-
ing/asthma and respiratory infections). According to
PRISMA-P guidelines,17 further speciﬁcation of the
range of outcomes considered and categorisation into
primary and secondary outcomes, is provided in the
Outcomes and prioritisation section. Studies reporting
at least one primary or secondary outcome in relation to
at least one intervention of interest are eligible. Studies
evaluating (indicators of) SHS exposure, surrogate out-
comes, smoking incidence or behaviour, or economic
outcomes only, are not eligible.
Timing
No restrictions regarding length of follow-up are
applicable.
Setting
There will be no restrictions with regard to study setting.
Language
No language restrictions will apply. We will seek transla-
tion for abstracts published in foreign languages, to
assess eligibility as well as for full reports of any poten-
tially eligible studies.
Report type
Articles published in scientiﬁc journals, as well
as reports in the ‘grey literature’, will be eligible.
For studies reported as abstracts only, authors will be
contacted to obtain necessary additional information.
Information sources
We will search for relevant published studies in the
following online data sources: Cochrane Library
(CENTRAL), Medline, EMBASE, PsychInfo, Cumulative
Index to Nursing and Allied Health Literature
(CINAHL), WHO Global Health Library (in addition to
MEDLINE covering African Index Medicus (AIM),
LILACS, Index Medicus for the Eastern Mediterranean
Region (IMEMR), Index Medicus for South-East Asia
Region (IMSEAR), Western Paciﬁc Region Index
Medicus (WPRIM), WHO Library Database (WHOLIS)
and Scientiﬁc Electronic Library Online (SciELO)),
IndMED, ISI Web of Science, KoreaMed, EconLit,
Paediatric Economic Database Evaluation (PEDE),
Google Scholar and the ProQuest database of PhD dis-
sertations. We will search for unpublished and ongoing
studies in the overarching WHO International Clinical
Trials Registry Platform (ICTRP). Searches will cover the
full time period available within each database up until
the search date. Although the MPOWER package was
introduced by the WHO in 2008, individual tobacco
control policies contained in MPOWER have been
implemented much earlier in various countries, with
evaluation studies of their health impact having been
published prior to MPOWER introduction.6 10
Search strategy
We will use a combination of MeSH terms and free text
to identify relevant studies from the online data sources.
Broad search terms will be used to ensure all relevant
studies are identiﬁed. The search strategy for MEDLINE
is provided as an example in the online supplementary
appendix. Speciﬁc search strategies will be tailored to
the different databases.
We will screen reference lists of articles of interest as
well as citations to articles of interest (using Google
Scholar) to identify any reports that may have been
missed by our search strategy. We will, furthermore,
consult an international panel of experts in the ﬁeld to
identify any additional and ongoing studies. This com-
prehensive approach has previously proved successful in
also identifying relevant ‘grey literature’ (eg, governmen-
tal and organisational reports), which is likely to consti-
tute an important share of the pertinent literature on
the subject.10 22
Study records
Data management
Records will be entered into an EndNote Library via
electronic extraction, or manual input, if necessary. The
library will be deduplicated electronically and then
checked manually to identify any remaining duplicates.
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Duplicates will be counted for reporting in a PRISMA
diagram.
Selection process
Two reviewers will independently screen titles and
abstracts of all unique records identiﬁed by the search
strategy. Based on consensus, and arbitration by a third
reviewer when necessary, records will be selected based
on title and abstract for further eligibility screening (ie,
reading the full report). Full reports for all selected
records will be read and assessed for eligibility inde-
pendently by two reviewers. Final selection of eligible
studies for inclusion in the review will be based on con-
sensus, with arbitration by a third reviewer, if necessary.
Should additional information be necessary to assess
eligibility of an individual study, we will attempt to
obtain such information by contacting the authors.
Reasons for exclusion at this stage will be speciﬁed and
reported in the PRISMA diagram.
Data collection process
Two reviewers will extract data onto customised data
extraction forms. These forms will be piloted using the
ﬁrst ﬁve studies identiﬁed and amended where neces-
sary. Disagreement regarding extracted data will be
resolved by consensus or arbitration by a third reviewer,
if necessary. We will contact authors of eligible studies to
obtain any relevant information that cannot be retrieved
from the original reports.
Data items
We will extract the following data items from each
report: author names, author afﬁliations, bibliographic
information (ie, publication year, journal or book, URL
if applicable), study funders, conﬂicts of interest
reported, study type, study site(s), study period(s),
description and timing of intervention(s) (including
some measure of degree/comprehensiveness), descrip-
tion of comparator, number of clusters and cluster sizes
(if relevant), number or participants, treatment group
sizes, inclusion/exclusion criteria, participant character-
istics (age, gender, socioeconomic status), outcome
measures and deﬁnitions, data sources used, baseline
and postintervention incidence/prevalence of each
outcome (for quasi-experimental studies), statistical
analysis technique(s) used, unadjusted and adjusted
measures of the association between the intervention
and outcome including CIs and/or p values, covariates
adjusted for (if applicable), bias assessment, adverse
effects, follow-up rate and handling of dropouts.
Authors will be contacted to obtain any relevant infor-
mation that is missing from the reports.
Outcomes and prioritisation
Primary outcomes are selected based on their recog-
nised associations with SHS exposure and their global
relevance to child health, considering prevalence and
severity; these are:
▸ Perinatal mortality (stillbirth+neonatal mortality);
▸ Preterm birth (live birth at gestational age
<37 weeks);
▸ Asthma exacerbations requiring hospital attendance
(emergency department visit and/or hospital
admission);
▸ Respiratory tract infections requiring hospital attend-
ance (emergency department visit and/or hospital
admission).
Secondary outcomes are:
▸ Mortality: stillbirth (born dead at gestational age
≥24 weeks), neonatal mortality (death within
28 days), early neonatal mortality (death within
7 days), late neonatal mortality (death between 7 and
28 days), postneonatal mortality (death between
28 days and 1 year), infant mortality (death in the
ﬁrst year of life), child mortality;
▸ Perinatal outcomes among live births: extremely low
birth weight (birth weight <1000 g), very low birth
weight (birth weight <1500 g), low birth weight (live
birth with birth weight <2500 g), birth weight (con-
tinuous scale), small for gestational age (birth weight
<10th centile for gestational age), very small for gesta-
tional age (birth weight <3rd centile for gestational
age), extremely preterm birth (gestational age
<28 weeks), very preterm birth (gestational age
<32 weeks), gestational age (continuous scale), con-
genital anomalies;
▸ Childhood outcomes: asthma, wheezing, respiratory
infections, upper respiratory infections, lower respira-
tory infections, otitis media with effusion, chronic
cough.
We will, from eligible studies that report any of the
above outcomes, also extract the following information
on evaluation of the potential underlying causal path-
ways, if provided:
▸ Changes in maternal (when pregnant) and/or child
SHS exposure
▸ Changes in maternal smoking during pregnancy
▸ Changes in paternal smoking behaviour
▸ Changes in child/adult smoking behaviour
Changes in smoking and/or SHS exposure may either
be reported or biologically conﬁrmed (preferable; eg,
via cotinine measurement in body ﬂuids such as saliva
or urine).
Risk of bias of individual studies
We will assess risk of bias for RCTs, CCTs and CBA
studies, using the suggested risk-of-bias criteria for
EPOC reviews,23 based on the Cochrane Collaboration’s
tool for assessing risk of bias (Table 8.5.a of the
Cochrane Handbook).24 For ITS studies we will use
EPOC criteria only.23 Observational studies will be
quality-assessed using the Effective Public Health
Practice Project (EPHPP) Quality Assessment Tool for
Quantitative Studies.25 Risk-of-bias assessment will be
performed independently by two reviewers, with any dis-
agreement resolved by consensus or arbitration by a
4 Been JV, et al. BMJ Open 2015;5:e008398. doi:10.1136/bmjopen-2015-008398
Open Access
group.bmj.com on February 21, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
third reviewer, if necessary. Risk of bias will then be
reported in detailed tabular form.
Data synthesis
Data will be grouped according to type of intervention
and reported in qualitative narrative and tabular form.
For each unique combination of an intervention and an
outcome of interest, we will extract point estimates and
corresponding CIs for effect sizes or association mea-
sures, henceforth referred to as effect measures, as
appropriate. For dichotomous outcomes, we will extract
risk ratios (RR) where possible. We will contact authors
to provide RRs if ORs are reported or otherwise estimate
these using the formula:
RR ¼ ORð1 PEERÞ þ ðPEER ORÞ
where PEER is the patient-expected event rate in the
control group. Unadjusted and adjusted effect measures
will both be extracted. When multiple adjusted effect
measures for the same combination of an intervention
and an outcome are reported, those derived from the
most adjusted model will be extracted.
Multiple studies will be combined using meta-analysis
when sufﬁcient similarity is present in the intervention
under study, in the study population, and in outcome
deﬁnition, as assessed independently by two reviewers
with arbitration of a third reviewer, if necessary. Given
anticipated heterogeneity between studies, random-
effects models will be applied in all analyses. For continu-
ous outcomes, we will analyse weighted mean differences,
or use standardised mean differences when different
measurement scales have been used across studies.
Adjusted effect measures will be favoured above
unadjusted effect measures for inclusion in meta-analysis.
Tax increases are often analysed on a continuous scale
when evaluating their impact on health outcomes.13 15
We will attempt to standardise the impact estimates from
different studies assessing the impact of tobacco taxes so
as to facilitate meta-analysis, as appropriate.
Clinical heterogeneity among studies will primarily
be assessed qualitatively through identiﬁcation of
differences in study design, inclusion and exclusion
criteria, setting, population characteristics, intervention
characteristics, outcome deﬁnition and ascertainment,
and statistical approach. If sufﬁcient clinical homogeneity
is considered to be present, I2 test will, in addition, be
used to quantitatively assess heterogeneity across studies.
Sensitivity analysis
Following EPOC guidelines, our primary analyses will be
restricted to RCT, CCT, ITS and CBA designs. In order
to assess potential bias introduced by this restriction, we
will, in a sensitivity analysis, reanalyse the data including
ﬁndings from any relevant UBA, prospective or retro-
spective cohort, case–control, and/or nested case–
control studies on the topic. We will perform additional
sensitivity analyses to evaluate the impact of study quality
on the association measures, by restricting the analyses
to low and moderate risk-of-bias studies.
Subgroup analyses
In order to inform policy deliberations in the ﬁeld, we
will, where possible, report outcomes according to the
comprehensiveness and/or degree of coverage of the
intervention (eg, type of environment covered for
smoke-free legislation, degree of tobacco tax increase,
stop-smoking medicines being free vs low-cost), in sub-
group analyses. Furthermore, given the large and
increasing global disparities in smoking and
smoking-related health outcomes,26 27 and the evidence
of differential impact of various tobacco control policies
on these disparities,11 15 27 28 we will, where possible,
report the impact of each intervention according to
socioeconomic status, alongside describing its overall
impact. In an attempt to further minimise potential
residual confounding by active smoking among children,
we will, where relevant, reanalyse the data after exclusion
of studies with active smoking rates >10% in the study
population.
Meta-analysis will be performed using Stata SE
(V.13.0) software.
Meta-bias assessment
Through our search strategy we will identify any studies
for which a protocol was registered but for which results
have not been reported, and we will check the study’s
status with the authors and obtain any data, if possible.
For each published study, we will assess whether a proto-
col was registered prior to undertaking the study. If a
protocol exists, we will assess whether any important
deviations were present in the study, such as selective
outcome reporting. We will construct funnel plots if >10
studies are combined in meta-analyses, to assess small
study effects that may suggest dissemination bias.
Confidence in cumulative estimate
On the basis of the combined evaluation of heterogen-
eity and risk-of-bias assessment across studies, study
results, and the results of any meta-analyses and meta-
bias assessments, we will provide an overall interpret-
ation of the strength of the evidence for an association
between each intervention and child health outcomes in
the Discussion of our report.
ETHICS AND DISSEMINATION
We will make use of aggregate-level data from prior
studies only, for which no ethical assessment is required.
We plan to report our study ﬁndings according to
PRISMA guidelines,29 in an appropriate international
peer-reviewed scientiﬁc journal. We will, in collaboration
with public and patient organisations, disseminate our
ﬁndings to the public.
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